US Industry Slams Russia And Turkey For IP And Market Access 'Failures'
Several European Countries Targeted For USTR Watch List
Executive Summary
Compulsory licensing in Russia, domestic production measures in Turkey, and clinical trial requirements for Germany’s pricing and reimbursement process come under fire in PhRMA's “Special 301” report to the US Trade Representative.